Fontan Udenafil Exercise Longitudinal Assessment Trial - 2

• Status: Recruiting
• Trial end date: 2025-10-28

Summary

This study will evaluate the clinical efficacy and safety of udenafil, an orally administered, potent and selective inhibitor of PDE5, versus placebo for the treatment of adolescent who have had the Fontan procedure.

• Phase: Phase 3

Details

• Lead Sponsor: Mezzion Pharma Co. Ltd
• Treatments: Udenafil